Related Experiment Video
Updated: Jan 19, 2026
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
Published on: February 10, 2015
Thymosinβ4 alleviates cholestatic liver fibrosis in mice through downregulating PDGF/PDGFR and TGFβ/Smad pathways
Cai Chen1, Xiankui Li2, Lei Wang3
1Teaching and Research Centre, Faculty of Medicine, Xinyang Vocational and Technical College, Xinyang, China.
Abstract:
Liver fibrosis is an important health problem without adequate and effective therapeutics. In this study, effects of thymosinβ4 (Tβ4) on hepatic fibrogenesis and the underlying molecular mechanisms were explored in bile duct ligation (BDL)-induced mice cholestatic liver fibrosis model. Results showed exogenous Tβ4 significantly reduced the mortality and liver/body weight ratio in BDL mice. Histological examinations and biochemical analyses demonstrated that BDL induced evident portal fibrosis and a significant increase in hepatic collagen contents. However, these changes were significantly attenuated by exogenous Tβ4. Quantitative real-time PCR assays showed that Tβ4 suppressed BDL-induced increases in many fibrotic genes expression including α-smooth muscle actin (α-SMA), collagen I, III and fibronectin, TGFβ1, TGFβR II, Smad2, Smad3, and PDGFRβ. Results from immunohistochemistry and Western blots also showed that Tβ4 reduced TGFβ1 and PDGFRβ protein levels in the liver tissues of BDL mice. In vitro studies using LX-2 cells demonstrated that Tβ4 could decrease PDGFRβ and TGFβR II levels in hepatic stellate cells. Taken together, findings in our present studies suggested that exogenous Tβ4 alleviated BDL-induced cholestatic liver fibrosis through downregulating PDGF/PDGFR and TGFβ/Smad pathways.
Insights
Thymosin beta 4 (Tβ4) significantly reduced mortality and liver fibrosis in a mouse model. Tβ4 works by downregulating key fibrotic pathways, offering potential therapeutic benefits for liver diseases.
Area of Science:
- Hepatology
- Molecular Biology
- Pharmacology
Background:
- Liver fibrosis is a significant health concern with limited treatment options.
- Cholestatic liver fibrosis, induced by bile duct ligation (BDL), serves as a model for studying fibrogenesis.
- Understanding the molecular mechanisms of liver fibrosis is crucial for developing effective therapies.
Purpose of the Study:
- To investigate the therapeutic effects of thymosin beta 4 (Tβ4) on cholestatic liver fibrosis.
- To elucidate the underlying molecular mechanisms by which Tβ4 influences hepatic fibrogenesis.
Main Methods:
- A bile duct ligation (BDL) mouse model was used to induce cholestatic liver fibrosis.
- Exogenous Tβ4 administration was evaluated for its effects on mortality and liver pathology.
- Gene and protein expression of fibrotic markers (e.g., α-SMA, collagen, TGFβ1, PDGFRβ) were analyzed using qPCR, immunohistochemistry, and Western blots.
- In vitro studies utilized LX-2 hepatic stellate cells to assess Tβ4's cellular effects.
Main Results:
- Exogenous Tβ4 significantly reduced mortality and the liver/body weight ratio in BDL mice.
- Tβ4 administration attenuated BDL-induced portal fibrosis and decreased hepatic collagen content.
- Tβ4 suppressed the expression of key fibrotic genes including α-smooth muscle actin (α-SMA), collagen I, III, fibronectin, TGFβ1, TGFβR II, Smad2, Smad3, and PDGFRβ.
- Tβ4 reduced TGFβ1 and PDGFRβ protein levels in vivo and in vitro, indicating downregulation of PDGF/PDGFR and TGFβ/Smad signaling pathways.
Conclusions:
- Exogenous thymosin beta 4 (Tβ4) demonstrates significant protective effects against cholestatic liver fibrosis in a mouse model.
- Tβ4 alleviates liver fibrosis by downregulating the PDGF/PDGFR and TGFβ/Smad signaling pathways.
- These findings suggest Tβ4 as a potential therapeutic agent for liver fibrosis.
